volume 7, issue 2, P321-329 2018
DOI: 10.21037/tcr.2018.03.17
View full text
Yan Sun, Rui Meng, Zheng-Yu Cheng, Chen Fan, Xiao-Ming Wei, Yun Yang, Gang Wu, Karsten Kristiansen, Jun Xue

Abstract: Background: Hepatocarcinoma (HCC) is often diagnosed at an advanced stage with poor prognosis. A non-invasive method concerning circulating tumor DNA (ctDNA) has been recognized as a promising biomarker. ctDNA has been widely studied to monitor tumor dynamics and measure tumor burden.However, the results of previous studies for biomarkers for HCC have generally been inconsistent and limited in clinical application.Methods: HCC usually represent a mixture of different cancer cell clones differing in mutation co…

expand abstract